Annals of Surgical Oncology

, Volume 20, Issue 3, pp 811–818 | Cite as

Microinvasive Breast Cancer: ER, PR, and HER-2/neu Status and Clinical Outcomes after Breast-Conserving Therapy or Mastectomy

  • Danielle N. Margalit
  • Meera Sreedhara
  • Yu-Hui Chen
  • Paul J. Catalano
  • Paul L. Nguyen
  • Mehra Golshan
  • Beth A. Overmoyer
  • Jay R. Harris
  • Jane E. Brock
Breast Oncology



Contemporary clinical outcomes of microinvasive breast cancer (MIBC), defined as no focus >1 mm, are not well characterized. We document the immunophenotype, incidence of axillary metastases, and rate of recurrence in a well-defined case series.


We reviewed 83 consecutive patients with MIBC from 1997 to 2005. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2/neu) receptor status were assessed. The cumulative incidence of local recurrence (LR) and nodal/distant recurrence was calculated. Predictors of recurrence were identified and effect estimates determined.


Fifty-two patients (63 %) underwent breast-conserving therapy (BCT) and 31 (37 %) underwent mastectomy. Sixty-one percent had ER-positive disease and 49 % had HER-2/neu-positive disease. Three (4 %) of 68 patients with sentinel node mapping or axillary dissection had single node micrometastases, and none had macrometastases or multiple nodes involved. Median follow-up was 6.4 years, with 6 LRs, 2 regional nodal recurrences, and 2 concurrent local/distant recurrences. The 5-year cumulative incidence of recurrence (local, nodal, or distant) was 5.3 % (95 % confidence interval [CI] 2.0–13.4) for all patients, and among BCT patients, the 5-year cumulative incidence of LR was 4.2 % (95 % CI 0.7–12.7). HER-2/neu overexpression was not associated with recurrence (P = 0.46). Close/positive margins (≤2 mm) were significantly associated with an increased risk of LR after BCT or mastectomy (hazard ratio 8.8; 95 % CI 1.6–48.8; P = 0.003).


MIBC has a favorable prognosis, and HER-2/neu overexpression, although highly prevalent, is not significantly associated with recurrence. Axillary metastases at diagnosis are small and infrequent. The cumulative incidence of LR after BCT is acceptable; however, our data confirm that negative margins (>2 mm) are required for optimal BCT outcomes.


Estrogen Receptor Local Recurrence Progesterone Receptor Human Epidermal Growth Factor Receptor Distant Recurrence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We thank Barbara Silver for editing and research support.


  1. 1.
    American Cancer Society. AJCC cancer staging manual, 6th ed. New York: Springer-Verlag, 2002.Google Scholar
  2. 2.
    de Mascarel I, MacGrogan G, Mathoulin-Pelissier S, Soubeyran I, Picot V, Coindre JM. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer. 2002;94:2134–42.PubMedCrossRefGoogle Scholar
  3. 3.
    Mirza NQ, Vlastos G, Meric F, et al. Ductal carcinoma-in situ: long-term results of breast-conserving therapy. Ann Surg Oncol. 2000;7:656–64.PubMedCrossRefGoogle Scholar
  4. 4.
    Padmore RF, Fowble B, Hoffman J, Rosser C, Hanlon A, Patchefsky AS. Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience. Cancer. 2000;88:1403–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Rosner D, Lane WW, Penetrante R. Ductal carcinoma in situ with microinvasion. A curable entity using surgery alone without need for adjuvant therapy. Cancer. 1991;67:1498–503.PubMedCrossRefGoogle Scholar
  6. 6.
    Schuh ME, Nemoto T, Penetrante RB, Rosner D, Dao TL. Intraductal carcinoma. Analysis of presentation, pathologic findings, and outcome of disease. Arch Surg. 1986;121:1303–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with microinvasion. Cancer. 1998;82:2382–90.PubMedCrossRefGoogle Scholar
  8. 8.
    Solin LJ, Fowble BL, Yeh IT, et al. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys. 1992;23:961–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Wong JH, Kopald KH, Morton DL. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg. 1990;125:1298–301.PubMedCrossRefGoogle Scholar
  10. 10.
    Parikh RR, Haffty BG, Lannin D, Moran MS. Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation. Int J Radiat Oncol Biol Phys. 2012;82:7–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Vieira CC, Mercado CL, Cangiarella JF, Moy L, Toth HK, Guth AA. Microinvasive ductal carcinoma in situ: clinical presentation, imaging features, pathologic findings, and outcome. Eur J Radiol. 2010;73:102–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Kwon JH, Kim YJ, Lee KW, et al. Triple negativity and young age as prognostic factors in lymph node–negative invasive ductal carcinoma of 1 cm or less. BMC Cancer. 2010;10:557.PubMedCrossRefGoogle Scholar
  13. 13.
    Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419–26.PubMedCrossRefGoogle Scholar
  14. 14.
    Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:2373–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Albert JM, Gonzalez-Angulo AM, Guray M, et al. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys. 2010;77:1296–302.PubMedCrossRefGoogle Scholar
  16. 16.
    Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27:5700–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Halasz LM, Sreedhara M, Chen YH, et al. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ. Int J Radiat Oncol Biol Phys. 2012;82:e581–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010;102:627–37.PubMedCrossRefGoogle Scholar
  19. 19.
    Stackievicz R, Paran H, Bernheim J, et al. Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ. Isr Med Assoc J. 2010;12:290–5.PubMedGoogle Scholar
  20. 20.
    Guth AA, Mercado C, Roses DF, Darvishian F, Singh B, Cangiarella JF. Microinvasive breast cancer and the role of sentinel node biopsy: an institutional experience and review of the literature. Breast J. 2008;14:335–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Intra M, Zurrida S, Maffini F, et al. Sentinel lymph node metastasis in microinvasive breast cancer. Ann Surg Oncol. 2003;10:1160–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Grin A, Horne G, Ennis M, O’Malley FP. Measuring extent of ductal carcinoma in situ in breast excision specimens: a comparison of 4 methods. Arch Pathol Lab Med. 2009;133:31–7.PubMedGoogle Scholar
  23. 23.
    Latta EK, Tjan S, Parkes RK, O’Malley FP. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol. 2002;15:1318–25.PubMedCrossRefGoogle Scholar
  24. 24.
    Park K, Han S, Kim HJ, Kim J, Shin E. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology. 2006;48:702–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Zavagno G, Belardinelli V, Marconato R, et al. Sentinel lymph node metastasis from mammary ductal carcinoma in situ with microinvasion. Breast. 2007;16:146–51.PubMedCrossRefGoogle Scholar
  26. 26.
    Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.PubMedCrossRefGoogle Scholar
  27. 27.
    Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291:1972–7.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2012

Authors and Affiliations

  • Danielle N. Margalit
    • 1
  • Meera Sreedhara
    • 1
  • Yu-Hui Chen
    • 2
  • Paul J. Catalano
    • 2
  • Paul L. Nguyen
    • 1
  • Mehra Golshan
    • 3
  • Beth A. Overmoyer
    • 4
  • Jay R. Harris
    • 1
  • Jane E. Brock
    • 5
  1. 1.Department of Radiation OncologyBrigham & Women’s Hospital/Dana-Farber Cancer InstituteBostonUSA
  2. 2.Harvard Cancer ConsortiumBrigham & Women’s Hospital/Dana-Farber Cancer InstituteBostonUSA
  3. 3.Department of SurgeryBrigham & Women’s Hospital/Dana-Farber Cancer InstituteBostonUSA
  4. 4.Department of Medical OncologyBrigham & Women’s Hospital/Dana-Farber Cancer InstituteBostonUSA
  5. 5.Department of PathologyBrigham & Women’s Hospital/Dana-Farber Cancer InstituteBostonUSA

Personalised recommendations